Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | CFD | P00746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316630 | 0.89 | ROCK2 (0.62) | ROCK2ROCK1MMP3 | |
| SCHEMBL353107 | 0.86 | ROCK1 (0.68) | ROCK2ROCK1 | |
| SCHEMBL18595010 | 0.86 | ROCK2 (0.59) | ROCK2ROCK1MMP3 | |
| SCHEMBL7141146 | 0.86 | ROCK2 (0.59) | ROCK2ROCK1MMP3 | |
| SCHEMBL7145427 | 0.84 | ROCK2 (0.67) | ROCK2ROCK1L3MBTL1 | |
| SCHEMBL7301734 | 0.84 | SMN1; SMN2 (0.67) | ROCK2ROCK1L3MBTL1 | |
| SCHEMBL525660 | 0.82 | ALDH1A1 (0.54) | L3MBTL1 | |
| SCHEMBL354603 | 0.82 | ROCK1 (0.50) | ROCK2ROCK1L3MBTL1 | |
| SCHEMBL10466253 | 0.82 | ROCK2 (0.55) | ROCK2ROCK1L3MBTL1 | |
| SCHEMBL18595025 | 0.82 | ROCK2 (0.55) | ROCK2ROCK1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2806899-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110578-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| CN-1355811-A | Integrain receptor antagaonists | BASF AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6297266-B1 | INHIBIT THE BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES OF CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1123283-A1 | THIAZOLE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | EP | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| WO-2000024724-A1 | THIAZOLE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | ROCK2 180/4885ROCK1 62/4885L3MBTL1 1072/4885 |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB1 | ROCK2 999/4885ROCK1 892/4885L3MBTL1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.